GET DAILY SIGNALSExagen (XGN): Analyst Targets Center on $10.50 After Sharp Sell-Off
Key Takeaways
- The central $10.50 price target is the arithmetic mean of seven current analyst price targets, which average $10.57 across a range of $9 to $12.
- At a recent price near $5.32 after a sharp post-earnings sell-off, reaching $10.50 would require roughly a 97% advance — a very large move.
- Analysts remain broadly bullish, with a "Strong Buy" skew built on pricing power, a new myositis test, and a path toward EBITDA breakeven.
- The biggest risks are decelerating AVISE CTD test volume, a wider adjusted EBITDA loss, and a new up-to-$50 million at-the-market share offering.
- The widest disagreement is between a $9 low and a $12 high, reflecting different views on how fast volume growth and profitability can recover.
- You can track Major News, Today's Price Move, the Forecast, and Earnings on dedicated pages for XGN.
- Explore Trending AI Robots for AI-driven ways to monitor changing conditions across the market.
Analyst Price Targets and Consensus View
Exagen Inc. (XGN) is a Nasdaq-listed precision medicine company focused on autoimmune diagnostics, best known for its AVISE CTD test used in diagnosing autoimmune diseases such as lupus. As a stock, its "price forecast" rests primarily on sell-side analyst price targets.
Seven current analyst price targets were reviewed, spanning approximately $9 to $12. The individual targets include $11 from Canaccord Genuity (raised from $9 on October 19, 2026), $11 from TD Cowen (raised from $10 on October 13, 2026), $11 from Roth MKM (raised from $9 in late September 2026), $12 from B. Riley Securities, and $9 from BTIG, with additional $10 targets from earlier 2026 notes. The arithmetic mean of these seven targets is $10.57, rounded to a central target of $10.50.
The range is notably wide relative to the share price. Bullish analysts emphasize sustained average-selling-price gains and the company's pipeline, while more cautious views reflect concerns about slowing volume growth and the timeline to profitability. No consensus should be read as a guarantee, and the mean is not an official published consensus figure. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
After its November 10, 2026 third-quarter report, XGN fell roughly 26% in a single session to near $5.32. From that level, reaching the $10.50 central target implies an advance of about 97% — a very large move by any standard.
The path depends on whether the company can reaccelerate test volume. Third-quarter revenue grew about 7% to $18.4 million, but AVISE CTD test volume rose only about 2%, down from roughly 11% in the prior quarter. Trailing twelve-month average selling price reached $451, a 14th consecutive quarterly increase, and full-year revenue guidance of $72 million to $75 million was reiterated. That pricing strength is carrying near-term growth while volume — the key driver of a diagnostic lab's revenue — has slowed sharply.
What Could Support a Move Toward the Target
- Fourteen consecutive quarters of average-selling-price gains, underscoring durable reimbursement and value-based pricing.
- Reiterated full-year 2026 revenue guidance of $72 million to $75 million, implying 8% to 13% growth.
- A new myositis test with clinical and analytical validation completed, targeting a launch in early 2027 in a potentially larger patient population.
- Fast-growing Pharma Services revenue, up roughly 85% year to date with a growing backlog.
- A stated objective of adjusted EBITDA breakeven at around $80 million in annual revenue.
What Could Prevent the Target From Being Reached
- Test volume growth decelerating to about 2%, which could signal softer demand or tougher comparisons.
- A widening adjusted EBITDA loss and rising operating expenses, delaying profitability.
- A new shelf registration for up to $150 million in securities, including a $50 million at-the-market program, which could dilute existing shareholders.
- Reimbursement pressure from payers and proposed PAMA (Protecting Access to Medicare Act) changes that could weigh on pricing.
- Seasonal fourth-quarter softness from fewer clinic days around the holidays.
Technical Levels and Market Structure
The stock's 52-week range extends from roughly $2.59 to above $10, meaning the $10.50 target sits near the upper end of recent trading history. After the post-earnings decline, XGN broke decisively below its 50-day moving average near $8, a level that now functions as potential resistance. The 200-day moving average near $5.06 sits just below the recent price and represents a key longer-term support zone. Reclaiming the psychological $7–$8 area would be an early sign of stabilization, while the $10 level acts as both a round-number resistance and the approximate prior high before any move toward $10.50 could be considered.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month horizon, though individual firms rarely disclose an exact date. Investors should watch the next quarterly earnings release and guidance, any updates on myositis test commercialization, the December 15, 2026 investor webcast on the pipeline, and whether the company draws on its new share offering program. Changes in analyst price targets, reimbursement decisions, and volume-growth trends will be the most direct signals on the path toward $10.50. From what I see, volume trends remain the critical variable to follow closely.
Using AI Tools for Ongoing Monitoring
In my view, tools like Tickeron’s AI Daily Buy/Sell Signals can provide an additional layer of insight when tracking names with wide analyst ranges and recent volatility. I’m watching this closely because automated signals based on technical behavior and market conditions help surface shifts that might otherwise require constant manual review, especially for smaller-cap healthcare stocks.
Final Assessment
Whether Exagen (XGN) can reach $10.50 depends on a reacceleration in test volume and continued pricing gains, set against dilution risk and a near-term profitability gap. The target reflects a calculated mean of $10.57 across seven analyst price targets ranging from $9 to $12, not a guarantee of future performance. From a recent price near $5.32, the required advance of roughly 97% is very large, and the analyst range itself signals genuine disagreement about the pace of recovery. The strongest supports are pricing power and the myositis pipeline; the principal obstacles are slowing volume, a wider adjusted EBITDA loss, and a new share offering. Investors should monitor volume trends, guidance, reimbursement decisions, and the December pipeline update before drawing any conclusions about the market outlook for XGN.
AI Daily Buy/Sell Signals
Tickeron's AI Daily Buy/Sell Signals have become a regular part of my routine for scanning opportunities in volatile names. The system continuously monitors thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a small-cap name like XGN, these signals help me spot potential trend shifts more efficiently alongside fundamental work, though I always cross-check them with the latest earnings and pipeline updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
XGN sees MACD Histogram crosses below signal line
XGN saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 06, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 37 instances where the indicator turned negative. In 33 of the 37 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XGN as a result. In 78 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
XGN moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for XGN crossed bearishly below the 50-day moving average on November 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where XGN's RSI Indicator exited the oversold zone, 33 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +11.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where XGN advanced for three days, in 190 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
XGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 160 of 185 cases where XGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.522) is normal, around the industry mean (67.298). P/E Ratio (-7.085) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.592) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. XGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases
Industry MedicalSpecialties
Advertisement